Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Hi everyone, and welcome to today's conference. This is Mattias Perjos, the CEO of Getinge. And with me today I have our CFO, Agneta Palmér. So in today's conference, we will go through our performance and some of the highlights from the second quarter before we open up for a Q&A. So we can move over to page number two, please. And as usual, let's start by looking at the development of our strategic KPIs. We continue to clearly track in line with plan to increase the share of sales from recurring revenue, accelerating the share of sales from high-margin products like, for example, our offering of consumables in infection control and beta bags in sterile transfer. This is all supported by solid and effective quality processes, and sales from recurring revenue continue to make up about two-thirds, and high-margin products are now at 70%. For quality, the number of field actions in relation to sales has decreased significantly, and we're pacing a lot better than last year. These improvements should, of course, be achieved through responsible leverage and also an attractive long-term return on invested capital. With that, we can move over to page number three, please. So if we zoom in on the second quarter and some of the financial key takeaways for the quarter overall, we delivered a healthy financial performance with solid top-line growth. Net sales grew 4.6% organically, with positive development in most of the business areas. Order intake increased by 6.2% organically. Adjusted gross and EBITDA margins were up in the quarter as a result of the IEEPA tariff refund, and also continued positive underlying performance in our business. This led to a strong cash flow and a strong financial position with financial leverage at 1.7 times, so well below the 2.5 times adjusted EBITDA as we have as our internal threshold; we can then move over to page number four and some of the key events in the quarter. So we take a step back here and look at some of the key events in our business across the second quarter. When it comes to the offering and customers, we continue to be innovative. In the quarter, we launched three products which will benefit customers and patients. We have launched the Aquadis Endo 110, which is the next generation of automated endoscope reprocessing, while the Fluobeam LS expands the fluorescence imaging portfolio for small incision surgery. We also launched the Vasoview Hemopro 3, which is the latest evolution of our EVT platform supporting coronary artery bypass grafting procedures. In Hamburg, Germany, we opened a digital innovation center with the purpose of accelerating the path to a more intelligent perioperative workflow. Furthermore, in Surgical Workflows, we strengthened our infection prevention offering in endoscopy by acquiring Pennamed, a UK-based distributor of endoscopic consumables. We, of course, also monitor the situation in the Middle East closely. Our first priority remains to tend to our employees in the region and continue to support our customers. The region makes up about 2% of sales, whereas Saudi Arabia is around half. And thanks to our team's diligent efforts to reroute shipments, to implement sourcing initiatives and also take other mitigating actions, the impact on both top line and costs has been very limited so far. Naturally, this might become more of a headwind if the situation worsens, and we continue to follow this very closely. If we then move to sustainability and quality, we reached an important regulatory milestone in June when we submitted the 510(k) application to the FDA for our Cardiosave intra-aortic balloon pump. I'm also happy to see that several of our sustainability KPIs are trending in the right direction. For example, when you look at the product quality KPIs and the greenhouse gas emissions noted here on the slide, as briefly mentioned. Also we. When it comes to our tariffs that we communicated separately, we did receive an IEEPA tariff refund in the quarter of approximately $36 million. We can then move over to page number five and we will discuss our top line performance. So when it comes to top lines, we start with order intake. The organic order intake in Acute Care Therapies increased primarily in ECLS therapy consumables, in our covered stents portfolio, and within Vasoview Hemopro 3. When it comes to Life Science, the organic order intake rose sharply during the quarter following double-digit growth in sterile transfer and in bioprocessing, while continuing to decline in other areas as a result of geopolitical uncertainty, the impact that this has on decision-making, and the continued challenging investment climate for pharma. The organic order intake for Surgical Workflows increased slightly, driven by a strong performance in infection control, while digital health solutions and Surgical Workflows services noted a decline in the quarter. Then, when it comes to net sales, we had 4.6% organic growth. Acute Care Therapies increased its net sales organically, primarily due to sales of stents, ECLS therapy consumables, as well as intra-aortic balloon pumps and consumables in the cardiac assist subsegment. In Life Science, organic net sales fell slightly despite robust growth in all product categories except for WIS and in Surgical Workflows. Organic net sales increased following growth in surgical workflows as well as service and consumables in infection control. So with that, we can move over to page number six, please. And I hand over to you, Agneta.
Thank you. Mattias. Overall, in addition to the IEEPA tariff refund, we improved our margins in the quarter thanks to leverage on increased sales and continued efforts with pricing, mix shift, and productivity. If we look at adjusted gross profit for the group, it amounted to 4,645 million SEK in the quarter, primarily on the back of the IEEPA tariff refund. Increased sales and price adjustments. This led to an increase of the adjusted gross profit margin by 4.6 percentage points in total. Adjusted EBITDA. The adjusted gross profit effect on the EBITDA margin was plus 4.8 percentage points, adjusted for currency. OPEX had a positive impact on the margin by about plus 1.1 percentage points in the quarter, and FX impacted negatively by -0.4 percentage points. All in all, this resulted in an adjusted EBITDA of 1,478 million SEK and a margin of 17.6%. Let's move to page seven, please. We remain in a solid financial position. Free cash flow in the quarter amounted to 1 billion SEK compared with 0.8 billion SEK in the prior year period. Free cash flow was impacted by improved operating profit and changes in working capital. At the end of Q2, net debt increased to 11.5 billion SEK on the back of the final earnout for the acquisition of Pennamed and the dividend. If we adjust for pension liabilities. Net debt is at 9 billion SEK. This brings us to a leverage of 1.7 times adjusted EBITDA, which is well below the 2.5 times which we have set as an internal threshold. If we adjust for pension liabilities, leverage is at 1.3 times adjusted EBITDA. Cash amounted to approximately 2.1 billion SEK at the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's move to page eight, please. And back to you, Mattias.
Okay. Great. Thank you very much. And besides the IEEPA tariff refund, the Q2 was the first quarter in a while with a cleaner year-on-year comparison, as the tariff also impacted Q2 2025. And even if there was still headwind from FX in this quarter, it has eased. So, looking then at the rolling 12-month development for adjusted EBITA margin, we were at 12.7% two years ago, and we are now at 15.2% normalized, which means that, excluding tariffs, we are at 15.5%. If we go back to the capital market update that we had in May 2024, we guided for an adjusted EBITA margin span of 16 to 19% by the end of 2028. We are about halfway through the period from 2024 to 2028, and we are closing in on this span here. The main drivers, which will support us there in spite of continued tariffs, are the gradual cost release from the second half of this year, primarily stemming from the regulatory submission and the future approval processes when it comes to Cardiosave and also Cardiohelp 2. And there is also the mix shift to more recurring and high-margin revenue. And there are also the results of our continuous productivity measures and some of the key product launches that we have ahead of us. With that, we can move to page number nine, please. So, in terms of the financial outlook for 2026, I think we are all aware of the situation. We live in uncertain times with a lot of geopolitical uncertainties that we need to navigate on a daily basis in our business. But based on the underlying demand that we see and our regular dialogue with customers, our expectation remains for organic net sales growth to be in the range of 3 to 5%, and this is adjusted for the phase out of our surgical perfusion product category. So, the perfusion is still expected to have some net sales in 2026, but declining from about 250 million to around 50 million SEK. We can then move to page 11, please. So, just to summarize the quarter before we head into Q&A. Overall, we had a robust financial performance with solid organic growth in the top line. Margins came in healthy thanks to the IEEPA tariff refund and also our improving underlying performance. Cash flow in the quarter and our financial position remain strong for 2026. We reiterate our guidance for organic net sales growth of 3% to 5%, adjusted for the phase-out of surgical perfusion. They remain the same as they have been from the beginning of this year. We continue to have the number one priority of addressing the remaining challenges in Acute Care Therapies. We are working on sustainability and productivity improvements, while maintaining cost consciousness to navigate this geopolitical uncertainty and address the impact from tariffs. And our number one priority, of course, is also to continue creating added value for our customers, which I think is something that we see on an everyday basis in our business. So with that, I open up for questions. Thank you very much.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Erik Castles from Danske Bank. Please go ahead.
Hi. Good morning everyone. First, I wanted to ask about the composition of organic order growth specifically for EMEA. Obviously very strong at 16%. And you are saying that mainly it seems to be due to ventilator orders. But I also wanted to ask you, is there any component of Cardiosave return and early Cardiohelp-i units that you are seeing now in order intake, and also on the Polish and Italian ventilator tenders. Were they sort of very significant and I guess non-recurring. Any color on both of those would be very helpful.
Yeah. Right. Thanks, Erik. We do not disclose detailed numbers on a product area level, but we do have some sales of both categories that you mentioned here and also a bit of an impact from sales in Poland, but we do not disclose detailed numbers of this. So there is an impact, but it is early days when it comes to both Cardiosave 2 and the shipments of Cardiosave.
Okay. Thank you. I also wanted to ask about sub-segment products as well, specifically regarding the order quality in Life Science, which was very strong, especially in the Americas. I just wanted to see if you could say anything about what is happening with the market over there. And also if you can talk about the mix between sterile transfer versus bioprocessing split, if there is anything nonrecurring in that order intake, or if it is just seeing the US market on a new, higher level.
I would say there is nothing non-recurring in there. It is sterile transfer continuing to trend very strongly, as it has for a while. And also in addition to this, we are seeing a better market climate when it comes to bioprocessing rather than on the negative side. As I mentioned on the call, we have a slightly more challenging situation when it comes to the Surgical Workflows business and the capital goods there. There is still some anxiety when it comes to our customers. And so that is a drag on the business. But there's nothing unusual or one-off in nature when it comes to the order intake. Otherwise, the outlook remains stable.
Okay, good. And just a quick one, are these types of orders, which I guess are mostly consumables looking at the mix in Life Science, converting relatively fast or is this order intake for the long term, so to say.
Sorry, which category were you talking about then?
Mainly sterile transfer, but overall consumables within Life Science.
I think there is some lumpiness when it comes to order patterns in consumables in Life Science. But again, there's nothing that stands out dramatically here, I'd say. And when it comes to the sales, it is a lot smoother regarding deliveries. So nothing out of the ordinary, I would say in the quarter as such.
Perfect. Thank you very much. I'll jump back in the queue.
Thank you.
The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.
Good morning. More product detail questions: I was wondering if you could share with us the growth rate and demand for your ECMO and intra-aortic balloon pump products. We guess we all saw one of the competing products out there having some issues and addressing them themselves. I was wondering if that has helped your products in the market.
Yeah. Thanks. Thanks. No, we have no evidence of that; I cannot talk about competitor positions here or anything that they have discussed in their earnings calls, but when it comes to our business, we basically continue to see the good trend that we have had for our business. And this is geographically very strong across the board also. And when it comes to the balloon pump business, we have started to release shipments for key markets and are ramping up the deliveries here as well. But I don't see a big connection between what other companies have communicated here and our growth, for us, it seems like normal, strong, and demand-driven.
Great. Thank you. And then my second question is, and this is more of a clarification; I think you mentioned in your remarks cost releases in the second half related to the upcoming launches. I was wondering if you could perhaps quantify those.
We have not put a number on this when it comes to the second half of this year. What we have said is really just reiterating what we have talked about for a few years now, that all the costs that go into remediating the two remaining categories in cardiopulmonary and in cardiac assist will start to come down in the second half of this year. So the overall number I'm talking about here is the 800 million SEK of extraordinary quality costs that we said peaked in 2024. So we had a little bit of a lowering of these costs. In 2025. We expect another lowering in 2026, mostly back-end loaded for '26. And then a little bit of a more rapid decrease of cost in 2027 and 2028.
Perfect. Thank you very much for the clarifications.
Thanks.
The next question comes from Ludwig Germander from Handelsbanken. Please go ahead.
Yes. Good morning, and thank you for taking my question. So first, I just want to follow up on the IABP ramp-up in key markets. Maybe you mentioned it, but would you say that there are any stocking effects at the moment since you are ramping up, or would you say that the sales and orders are fairly true to the underlying demand?
Yes, we are still supply constrained, so there is no possibility for anyone to stock any of the balloon pumps that we have started to ship here. We really have just been able to meet the most critical and urgent customer demand.
Okay, great. Thank you. Secondly, I just wanted to focus a bit on Acute Care Therapies margins here. So could you help us understand and maybe elaborate a bit on the underlying margin development for Acute Care Therapies specifically, if we adjust for tariff refunds, how should we think about that?
Yeah. Go ahead. Yeah.
No. So the majority of the tariff refund is related to Acute Care Therapies. But underlying margin performance is rather strong, connected to those factors that Mattias also mentioned. It is a mixture. It is the high-margin disposables that come through. It is continued pricing efforts. And it is those productivity initiatives. So underlying margin development is strong, but it is boosted by this IEEPA tariff refund.
Thank you. And then just a quick final one, if I may. So recently, there have been some discussions regarding US hospital CapEx levels. I was just curious if you could share anything about what you are currently seeing in the US and if you have noticed any change recently in customer dialogues?
No, we have the same data as everybody else here, and I can only comment on what we see. And we actually have seen this since almost a year back in some of the data from our customers as well. But we are very close to the strongly needed Acute Care Therapies. So we haven't had any real demand impact from our perspective. And I think, as I alluded to in the call, the continued dialogue that we have on an everyday basis with our customers is still rather positive. Customers seem to be willing to invest in the type of products and therapies that we offer because it's something that is needed to treat patients on an everyday basis.
Great. Thank you for taking my questions.
Thank you.
The next question comes from Christopher Lilleberg from DNB Carnegie. Please go ahead.
Hi. Thank you. Two questions, first. Could you just update us on the call you held previously? Hopefully, provide some status updates. And also, I am curious to hear your view now about the potential to lift margins for the full year. And also, if we adjust for this IEEPA tariff refund that you had, will there be more of that in the second half of the year? Thank you.
Yeah. When it comes to the Cardiosave, you have a limited market release. This issue that you mentioned has been resolved. So we are back into the final phase of that. And then of course, in the coming months, we will move into a full market release. So that issue is behind us when it comes to the margin guidance. We do not give detailed guidance for 2026. But we have mentioned earlier that our ambition is to improve the reported margin. Also this year. We have not changed that at all, but we are not prepared to give any more detailed guidance. Now, when it comes to the tariffs. We have, of course, reported what has been refunded to us and also how this is reported in the financial numbers, and we will continue to report forward-looking information from here on regarding what tariffs we end up paying. But underlying that, as of next week, there is a new tariff regime coming into place. We do not know exactly what this is. So we will continue to update you once we have clarity on this. But our intention is to continue to report tariffs paid going forward.
Could I ask a follow-up on what you said about margin? Would you say that the second quarter underlying margin development was according to what you were planning earlier this year, or have you become more confident in this margin recovery we see now.
Of.
The second quarter?
I think the drivers of the margin, if we disregard the tariffs, the other drivers of the margins—when it comes to the impact from leverage on growth, product mix, and the productivity improvements that we have—are broadly tracking according to the plans that we have. So maybe some additional comfort from this. But I think for us, there is no major surprise. We can see this development on a day-to-day basis as we follow up on everything that we do.
Thank you very much.
Thank you.
The next question comes from Mattias Perjos from SEB. Please go ahead.
Hi. Thanks for taking my questions. First, zooming out on APAC, here in this quarter overall, there was a drop in orders and sales, although nothing material. But could you just describe the climate that you see in the region, perhaps specifically covering key drivers in China.
I think China, like we've said for some time now, we expect to be a challenging market for the foreseeable future. Last year we did have around 2% growth in China. We don't guide on individual markets, but I think the headwinds are well known per category. They are quite well known by now. There is no particular dynamic to call out. I think China was one of the weak points in the quarter from a geographic perspective, but it is also something that fluctuates between quarters. So I think we have no reason to revise our outlook or anything when it comes to the evolution in APAC overall or China in particular. I think the categories within Acute Care Therapies that we have strong positions in continue to have a good demand situation. Surgical Workflows, on the other hand, we have had some strong competitive pressure for quite some time. And that has also continued now in Life Science, which is a little bit more diverse depending on which product category you look at. So from a demand perspective in China, there is nothing to call out. We expect this to continue to be challenging, but I think our team locally is doing a very good job in navigating this also.
Good. Thank you. The next question relates to ventilators. It seems to be doing well. How would you describe the comparison figures as you move into the second half of the year compared to what you have experienced in the first half? Are they easing up?
We have had some positive boost from this ventilator conversion that was going on and impacted the comps last year. We saw some of that remaining in Q2, but I think Q3 and Q4 are cleaner from that perspective. And overall, the ventilation market has stabilized quite well after all this post-COVID turbulence, and we continue to protect and develop our market share.
Good. Final question is, what is a reasonable timeline from now as to when you are able to sell Cardiosave and the full offering in the US without restrictions based on your knowledge?
Yeah. Yeah. Yeah. That is an important question, but very difficult to give. Give a timeline when it comes to the timeline, the part that we can impact, which means the submissions of 510(k) applications. I think we're on top of that. So, as I mentioned on the call, we have submitted the 510(k) application for our intra-aortic balloon pump. When it comes to the ECMO indication, it is the second half of the year. And we will come back specifically when that happens as well. But no change to plans or the timeline when it comes to submissions, although the approval process is a dialogue that we have with the FDA and not something I can give you any guidance on.
So head to toe is both a help and then.
It's the complete submission. Yes. For US indication, which means both hardware and consumables.
Perfect. Thank you.
The next question comes from Philip Wetterqvist from SB One Markets. Please go ahead.
Good morning guys. Uh, thank you for taking my questions. I will take them one by one. First, you mentioned price adjustments as a contributor to growth. So I'm wondering how much that contributed? You mentioned in Q4 that you expected prices to contribute about 2% for the full year. Does that still stand, or have you been able to increase prices further?
Yes, it is around the same level. So no change here.
All right. Perfect. Thank you. And then on life science, growth declined despite solid development in all categories except in wash. So how big of a part of Life Science sales is our legacy portfolio, let's say?
We don't disclose detailed numbers on the categories, but it is the legacy part of our portfolio. I think it is the longest offering that we have had in the market. And it consists of capital and service close to around 50/50 for those, but no detailed numbers on exactly the size of the business, but it is the one with the strongest headwind in Life Science right now.
Okay. And my last question is on field actions. You report field actions per $6 billion. It was up quarter-over-quarter by 0.1. What was the reason for that increase?
We do not disclose detailed field actions. I believe the information you can obtain is from what is officially published by regulatory authorities here. So, no other particular drivers to call out here. This is also something that can vary quite a bit over the quarter. So nothing to call out here in terms of product categories or geographic markets.
Okay. Thank you. That was all for me.
All right. Thank you.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from David Adlington from JP Morgan. Please go ahead.
Morning guys. First question just on the revenue guidance, you've achieved 2.7% year to date. I just wondered if the top end of the range at 5% is really in scope. And what are the drivers? What drives the acceleration in the second half to get there? Thanks.
Yeah. We are not going to break down the guidance range into any more detail here. We have fairly good momentum and reiterate the guidance, and when it comes to the demand drivers, I'd say overall, it's what we've talked about for a while; we do see good traction when it comes to the cardiopulmonary business and the ECLS therapy products that we have, and we expect sterile transfer to continue to be a strong point as well within Life Science. But we can't give you any more details on where we expect to land and what's required in terms of the guidance here.
Okay. Fair enough. And then just on margins, on the cost inflation side, is there anything you want to call out in terms of additional cost inflation, either the impact on the second half or into next year. Thanks.
This is something we're monitoring very, very closely. So far, we haven't seen any significant impact. I think the biggest individual impact has been when it comes to transport and transport surcharges. But again, not material at this stage. We continue to monitor all different categories very closely. And as you know, we have had a productivity program in place for quite a while; we were hoping maybe for some of these benefits to drop through to the bottom line, but right now they have more of a mitigating effect towards some of the inflationary pressures that we see. So, definitely on our radar, and thus far manageable. And I think we will be able to offset hopefully most of this with the continued productivity improvements that we're working on.
Perfect. That's good. Thank you. And then just finally on the IABP, you say you are supply constrained. Are you planning on ramping up capacity, and if so, when do you expect to be able to meet demand?
I cannot provide a specific timeline. We are continuously ramping up capacity here, but there are some constraints when it comes to components. And also when it comes to labor and ramping up. So, as you know, we have had a lot of capacity constraints because of the remediation program and having to do quite a lot of testing when it comes to products and so on. So it is an upward trajectory. I cannot give you a timeline for when we will be in balance.
Okay, great. Thank you.
Thank you.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
All right. Thank you very much. Thanks for tuning in. I think we have already made it through the summer, so I appreciate you taking the time to be with us today and wish you a great rest of the day. Thank you very much.



















